Published in Healthcare Mergers, Acquisitions and Ventures Week, August 1st, 2009
the high end of Abbott's second-quarter guidance range of $0.87 to
$0.89. Diluted earnings per share under Generally Accepted Accounting
Principles (GAAP) were $0.83. -- Worldwide operational sales, which excludes an unfavorable 8.0 percent
effect of exchange rates, increased 10.5 percent. Reported sales,
including the impact of exchange, increased 2.5 percent. Excluding the
expected decline in Depakote sales...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.